Meridian Bioscience is a pharmaceuticals business based in the US. Meridian Bioscience shares (VIVO.US) are listed on the NASDAQ and all prices are listed in US dollars. Meridian Bioscience employs 690 staff and has a trailing 12-month revenue of around $333 million.
Only you can make the decision on the time to leap... but here's some supporting information and analysis.
The gauge below shows real-time ratings that are based on 26 popular indicators such as moving averages, for specific time periods. It's not a recommendation but is simply technical analysis that can form part of your research.
Finder might not agree with the analysis and we take no responsibility. We also give no representations or warranty on the accuracy or completeness of the information provided on this page.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an adviser or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Valuing a stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of overall performance. However, analysts commonly use some key metrics to help gauge value. Check out the Meridian Bioscience P/E ratio, PEG ratio and EBITDA
Meridian Bioscience's current stock price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 35x. In other words, Meridian Bioscience stocks trade at around 35x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the United States stock markets on average as of November 09, 2023 (20.44). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Meridian Bioscience's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.33. A PEG ratio over 1 can be interpreted as meaning shares are overvalued at the current rate of growth, or may anticipate an acceleration in growth.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Meridian Bioscience's future profitability. By accounting for growth, it could also help you if you're comparing the stock prices of multiple high-growth companies.
Meridian Bioscience's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $92.1 million.
The EBITDA is a measure of a Meridian Bioscience's overall financial performance and is widely used to measure a its profitability.
A look at GSD Capital’s highlights, limitations, fees and investment strategies.
Explore the best bonuses for opening a new brokerage account.
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
Compare the 5 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
We rate robo-advisors across eight key categories, including ongoing costs, minimum deposit requirements, portfolio mix and more.
A beginner-friendly investing platform with fractional shares and no commissions on stocks and ETFs.
SoFi is a commission-free platform with both active and automated investment accounts.
What you need to know about investing in the leading indicator for the overall US stock market.
Take advantage of $0 trades and no investment minimums with this well-known broker.
A deep dive into the highlights and limitations of Robinhood.